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Abstract. Limited numbers of studies include research of microvibration therapy in experimental 
models. We examined effects of chronic vibroacustic-microvibration treatment on haemodynam-
ics and anti-oxidative defense in experimental hypertension. Study was performed on chronically 
treated hypertensive and normotensive Wistar rats. Mean arterial pressure (MAP), cardiac output 
(CO), renal blood flow (RBF), glomerular filtration and activity of anti-oxidative enzymes were
determined after three weeks treatment. Vibroacustic treatment had no influence on MAP and
CO, but RBF was increased in both groups of treated rats. Additionally, vibroacustic treatment 
enhanced diuresis and increased glomerular filtration in hypertensive rats. Glutathione peroxidase
(GSH-Px) activity was elevated in both treated rat strains, but activity of superoxide dismutase 
was unchanged. We conclude that microvibration treatment doesn’t ameliorate hypertension but 
improves renal blood supply (trough diminished renal vascular resistance), glomerular filtration,
diuresis, and enhances glutathione dependent anti-oxidant defense with more important beneficials
in hypertensive animals. 
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Introduction
Vibroacoustic may be defined as the process of propaga-
tion of sound vibrations through the body, considering 
that body of animals and humans is consists of cells that 
naturally vibrate in sound frequencies (Boyd-Brewer 
and McCaffrey 2004). In the middle of the last century,
Rohracher (1946) claimed firstly that the entire surface
of the human and homothermic animal body exhibits 
continuous microvibrations with frequency 7–13 Hz due 
to muscular and cardiac activity. During the last 30 years 
vibroacoustic therapy is used in clinical treatment (seda-
tive music and pulsed, sinusoidal low frequency tones 
20–70 Hz, played through a bed or chair). There has been
a substantial amount of research investigating vibratory 
sensitivity in subjects including infrasound, ultrasound, 
noise and music. Clinical benefits include: pain reduc-
tion, muscle relaxation, better joint and muscle flexibility,
improved blood circulation and better sense of well-being 
(Lundeberg et al. 1988; Kerschan-Schindl et al. 2001; Sands 
et al. 2006). So far, most studies investigating the effect of
vibration on blood flow have used frequencies common
among tools used in industry which generally means 80 
± 100 Hz (Kerschan-Schindl et al. 2001). Nevertheless, 
there is limited number of studies included in research of 
vibroacustic effects on blood flow and arterial pressure as
well as oxidative stress in experimental models.
Considering hypertension as one of the most prevalent 
and powerful contributors to cardiovascular diseases, and 
the spontaneously hypertensive rat (SHR) as most com-
monly used model for studies of human essential hyper-
tension (Doggrell and Brown 1998), we tried to examine 
effects of chronic vibroacustic microvibration treatment on 
both haemodynamic status and anti-oxidative defense in 
experimental hypertension and normotension. 
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Materials and Methods
Animals and vibroacustic device
The experimental protocol was approved by the Ethic Com-
mittee of the Institute for Medical Research, University of 
Belgrade, Serbia (No 0312-1/10). Study was done according 
to the Serbian National Law on Animal Welfare. It consisten-
cies with: guidelines for animal research and principles of 
the European Convention for the Protection of Vertebrate 
Animals Used for Experimental and Other Purposes (Of-
ficial Daily N. L 358/1-358/6, 1986) and Directive on the
protection of animals used for scientific purposes (Directive
2010/63/EU of the European Parliament and of the Council, 
2010). 
Six months old male SHR and age/sex matched nor-
motensive Wistar rats weighing about 300 g (bred at the 
Institute for Medical Research, University of Belgrade, 
Serbia) were used. The rats were housed in polyethylene
cages in temperature and humidity controlled rooms on 
a twelve-hour light-dark cycle, with free access to food 
and water. 
For animal treatment we used vibroacustic device Vita-
fon-T (gift from FIP-Komerc Belgrade, Serbia) in variable
frequency range of 30–4500 Hz, amplitude range 2.8–5.4 μm, 
impulse modulation 05–1.2 s, as specified on device manual.
This mod (No. 2) is recommended by manufacture as ben-
eficial in human hypertension.
Experimental groups and protocols
In all animals, systolic blood pressure and heart rate were 
indirectly measured using a tail-cuff pneumatic pulse
detector and a direct recorder (Physiograph Four, Narco 
Bio-System, Houston, TX, USA). Two separate baseline 
determinations of body mass and systolic blood pressure 
were made in a span of 4 days and then rats were divided 
into following groups:
• Wistar C – control normotensive rats (n = 9)
• Wistar V – vibroacustic treated normotensive rats (n = 
12)
• SH C – control hypertensive rats (n = 10)
• SH V – vibroacustic treated hypertensive rats (n = 11).
Conscious animals were treated with vibroacustic device 
10 minutes per day during 3 weeks. The first vibroacustic
transmitter was placed ventrally (on the abdomen surface) 
and the second dorsally (upon the kidney area). Transmit-
ers were fixed to the animal body by elastic strips. Control
animals were fitted only with elastic strips (at the same
treatment period). After three weeks treatment, all animals
had placed in metabolic cages for 24 hours urine collection, 
treated again and than preceded to the haemodynamic 
measurement. 
Haemodynamic measurements
Haemodynamic studies were performed in anesthetized 
(pentobarbital, 35 mg/kg i.p.) adult male spontaneously hy-
pertensive rats (SHR), and age/sex match normotensive Wistar 
rats. Mean arterial pressure (MAP) and heart rate (HR) were 
measured through a femoral artery catheter (PE–50, Clay-
Adams Parsippany, NY, USA), connected to the physiologi-
cal data acquisition system (9800TCR Cardiomax III-TCR, 
Columbus, OH, USA). Cardiac output (CO) was measured 
by thermodilution. A jugular vein was cannulated with poly-
ethylene tubing PE-50. Thermo sensor was placed in a left
carotid artery and coupled to the Cardiomax III. The second
thermocouple was placed in cold saline. Than, cold saline (0.2
ml) was administered through the jugular vein and mean arte-
rial pressure (MAP) and CO were recorded. Total peripheral 
vascular resistance (TPVR) was calculated by dividing MAP 
(mmHg) with CO (ml/min kg; assuming that mean right atrial 
pressure is zero) and expressed as mmHg·min·kg/ml.
For the renal blood flow (RBF) measurement, after ab-
dominal incision the left renal artery was gently separated. 
An ultrasonic flow probe (1RB, internal diameter = 1 mm)
was placed around the artery, and connected to the Tran-
sonic T106 Small Animal Flowmeter (Transonic System 
Inc., Ithaca, NY, USA). Renal vascular resistance (RVR) was 
calculated by dividing MAP (mm Hg) with RBF (ml/min kg) 
and expressed as mmHg·min·kg/ml. 
Biochemical measurements
At the end of the haemodynamic study blood samples were 
taken for determination of creatinine (PCr) and urea (PU) in 
plasma, as well as erythrocyte antioxidant enzymes activity. 
Than, all rats were sacrificed according to the animal ethical
guidelines. Lithium-heparin (Li-heparin, Sigma, USA) was used 
as an anticoagulant. We used previously collected urine samples 
for determination of creatinine (UCr) and urea (UU) in urine. 
All biochemical parameters were calculated using an automatic 
Cobas Integra 400 plus (Hoffmann-La Roche, Germany) ana-
lyzer. Creatinine and urea clearances (CCr; CU) were calculated 
on the basis of: UCr and UU, PCr and PU, urine volume and body 
weight, using the standard equation for clearance. 
Blood samples were centrifuged at 3000 rpm at 4°C for 
15 minutes and erythrocytes were separated. Hemoglobin 
(Hb) content was estimated by the method of Drabkin and 
Austin (1935). Spectrophotometric analyses of erythrocyte 
antioxidant enzyme activities were performed with Ultro-
spec 3300 pro UV/Visible spectrophotometer (Amersham 
Biosciences Corp., USA). 
Glutathione peroxidase (GSH-Px) activity was determinat-
ed according to the previously described method suggested by 
Paglia and Valentine (Paglia and Valentine 1967). The GSH-
Px activity was expressed as unit per gram of hemoglobin (U/g 
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Hg). One unit of GSH-Px was defined as μmol of oxidized
NADPH per minute per gram of hemoglobin. 
Activity of superoxide dismutase (SOD) was measured by 
spectrophotometry, using previously described method of 
epinephrine autoxidation (Misra and Fridovich 1972) and 
expressed as U/g Hb. 
Statistical analysis 
The results are shown as the mean ± SEM. We used the single-
sided Student’s t-test for two-samples of equal variance (Mi-
crosoft Excel 2010) for comparison between two examined
groups. There were compared control Wistar and SH groups
and, on the other hand, vitaphoned groups vs. their respective 
controls. The value p < 0.05 was considered notable. 
Results
Haemodynamic parameters
Arterial blood pressure was significantly increased in SHR
in comparison to Wistar rats (p < 0.001). Vibraphone treat-
ment changed neither blood pressure nor heart rate in both 
Table 1. Haemodynamic parameters in experimental groups after vibroacustic treatment







Wistar C (n = 9)  101 ± 5.11  347.67 ± 10.59  233.38 ± 13.25  0.815 ± 0.063
Wistar V (n = 12)  93 ± 6.45  337.83 ± 9.58  260.28 ± 16.77  0.840 ± 0.053
SH C (n = 10)  154.6 ± 4.82***  359.70 ± 17.94  214.63 ± 12.73  0.547 ± 0.031***
SH V (n = 11)  161.45 ± 5.29  388.45 ± 10.48  246.40 ± 17.85  0.620 ± 0.047
Wistar C, control normotensive rats; Wistar V, vibroacustic treated normotensive rats; SH C, control hypertensive rats; SH V, vibroacustic 
treated hypertensive rats; MAP, mean arterial pressure; HR, heart rate; CO, cardiac output; SV, stroke volume; *** p < 0.001 vs. Wistar C; 
n, number of animals.
Figure 1. Renal haemodynamic parameters and total vas-
cular peripheral resistance in experimental groups after
vibroacustic treatment. Wistar C, control normotensive 
rats; Wistar V, vibroacustic treated normotensive rats; 
SH C, control hypertensive rats; SH V, vibroacustic treated 
hypertensive rats; * p < 0.05 vs. Wistar C; *** p < 0.001 vs. 
Wistar C; # p < 0.05 vs. SH C; n, number of animals.
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Figure 2. Creatinine/urea clearances and urine output 
in experimental groups after vibroacustic treatment.
Wistar C, control normotensive rats; Wistar V, vibroacustic 
treated normotensive rats; SH C, control hypertensive rats; 
SH V, vibroacustic treated hypertensive rats; * p < 0.05 vs. 
Wistar C; ## p < 0.01 vs. SH C; n, number of animals.
normotensive and hypertensive rats (Table 1). There were no
differences in CO between the groups, while stroke volume was
significantly reduced in control SHR in comparison to control
Wistar rats (p < 0.001). Treatment with vibroacustic micro 
vibrations had no influence on this parameter too (Table 1).
Long-lasting hypertension was associated with increased 
TPVR in SHR (Figure 1) compared to normotensive rats 
(p < 0.001). Microvibrations significantly reduced TPVR in
SHR (p < 0.05). RBF was increased in both Wistar and SHR 
vibroacustic treated rats in comparison to their respective 
controls. This increasing was significant in normotensive
animals (p < 0.05) and moderate in hypertensive rats. On 
the other hand, RVR was significantly decreased in both
Wistar and SHR vibroacustic treated rats in comparison to 
their respective controls (p < 0.05), (Fig. 1). 
Biochemical parameters 
Urine output was increased in SHR in comparison to Wistar 
rats (p < 0.01). Vitafon-T treatment additionally enhanced 
diuresis in SHRs, compared to their controls (p < 0.01). 
Also, vibroacustic treatment increased glomerular filtra-
tion (expressed via both urea and creatinine clearances) in 
hypertensive rats (p < 0.05), (Fig. 2).
Activity of GSH-Px was elevated in SHR in comparison to 
Wistar rats (p < 0.001). Vibroacustic treatment additionally 
increase GSH-Px activity in both rat strains in comparison 
to their respective controls (p < 0.001 in Wistar treated and 
p < 0.05 in SHR treated rats) (Fig. 3).
Activity of SOD was diminished in SHR compared to 
Wistar rats (p < 0.01). Microvibration treatment didn’t influ-
ence this activity in both rat strains (Fig. 3).
Discussion
Vibroacoustic therapy is a treatment method based on low 
frequency sound vibration (microvibrations). Except music 
therapy (Curtis et al. 1986; Chesky et al. 1996) there are very 
limited data related to microvibration effects on haemody-
namic parameters, especially in any animal model. In this 
study we have used chronically-induced vibroacoustic mi-
crovibrations to evaluate their influence on cardiovascular
and oxidative parameters in normotensive and hypertensive 
rats. Our results show that 10 minutes variable vibroacoustic 
microvibrations have no influence on blood pressure and
heart rate in both rat strains after three weeks treatment.
Boughner and Roach (1971) showed that acute treated 
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carotid artery of humans failed to dilate to the low (70 Hz) 
and middle range (160 Hz) external vibroacustic stimula-
tion, but did dilate to a vibration of 325 Hz. On the other 
hand, considering blood pressure homeostasis, results of our 
study indicate that both rat strains had adaptive potential 
against prolonged microvibration treatment. This indicates
effective both fast blood pressure control and vascular re-
activity which were unaffected with microvibration stimuli.
Long-lasting hypertension followed by prolonged pressure 
overload and progression of cardiac hypertrophy expect-
ably diminished stroke volume in SHR (Pfeffer et al. 1982).
Vitafon treatment didn’t affect this deterioration, which
directed us to conclude that chronic microvibrations nei-
ther induced sustained positive inotropic effect on cardiac
muscle nor elicited large artery vasodilatation. This opinion
is further supported by unchanged cardiac output in vibra-
phone-treated animals and, on the other hand, by reduced 
total peripheral vascular resistance in treated SHR. Besides, 
diminished vascular resistance implies predominantly pe-
ripheral effects of microvibrations, probably due to small
artery vasodilatation. This is in accordance with Lohman
et al. (2007) who suggested that short-term vibration alone 
significantly increased peripheral blood flow in skin, mini-
mum of 10 minutes following intervention. Development of 
hypertension in SHR is characterized by elevated renal vas-
cular resistance (Schnackenberg et al. 1998) as a reflection of
marked endothelial dysfunction in renal artery vasculature. 
Vibroacustic treatment in our experimental design elevated 
blood flow and significantly reduced vascular resistance in
the left renal artery of both Wistar and SHR. It was reported
(Kerschan-Schindl et al. 2001) that vibrations significantly
increased blood cell velocity, therefore increased a blood 
flow. Our study revealed this point through improved renal
artery haemodynamic and enhanced kidney blood supply 
in both vibraphoned rat strains. These effects are more
important in hypertensive animals indicating beneficial
properties of vibroacustic treatment in conditions with 
endothlelial and renal dysfunction such as hypertension. 
Beside increased blood cell velocity, there is possibility 
(suggested by manufacture) that variable micro vibrations 
directed blood vessels as hydrodynamic pumps to more 
effective blood circulation. Further, amelioration of renal
artery haemodynamics was followed by glomerular filtra-
tion increasing and enhanced urine output in SHR. There is
evidence that advanced hypertension in SHR seems to start 
a renal vicious circle, because accentuated reductions of fil-
tration capacity are paralleled by structural postglomerular 
resistance increases, apparently to maintain glomerular 
filtration rate by raised filtration pressure which, however,
accelerates glomerular deterioration (Göthberg and Folkow 
1983). By our opinion, glomerular filtration and urine out-
put improvement in vibraphoned SHR is reflection of renal
blood flow enhancement due to microvibration-induced
increasing of blood cell velocity, as previously reported by 
Kerschan-Schindl et al. (2001). 
Previous studies indicate that SHR, as an animal model 
of human essential hypertension, shows elevated RBC 
glutathione level as an adaptation against oxidative stress 
in vivo related to genetic hypertension (Yuan et al. 1996). 
Our results indicate that vibroacustic treatment additionally 
stimulates activity of GSH-Px, leading to more effective oxi-
dative defense in this hypertensive strain. On the other hand, 
activity of SOD was unchanged in both vibraphoned strains 
in comparison to their respective controls. There is evidence
that SOD activity is reduced in hypertensive patients as well 
as in SHR (Ito et al. 1995). Similar results we obtained in 
SHR in our presented study. SOD rapidly converts O22 to 
the less reactive H2O2 that is further degraded by catalase 
and GPx. Besides, the expression of GPx can be stimulated 
during excessive exposure to H2O2 (Erden and Bor 1984), 
produced either by enhanced SOD activity or by direct oxi-
dative production from other sources (Arduini et al. 1988). 
Unchanged SOD activity in our experimental design suggests 
that H2O2 is originated from other sources, probably due to 
intensive oxygenation after microvibration treatment. On the
other hand, significantly elevated GSH-Px activity in vibra-
phoned animals expresses potential to effectively neutralize
consequences of this excessive oxygenation.
Figure 3. Activities of glutathione peroxidase (GSH-Px) and 
superoxide dismutase (SOD) in experimental groups after vibroa-
custic treatment. Wistar C, control normotensive rats; Wistar V, 
vibroacustic treated normotensive rats; SH C, control hypertensive 
rats; SH V, vibroacustic treated hypertensive rats; *** p < 0.001 vs. 
Wistar C; # p < 0.05 vs. SH C; n, number of animals.
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Taken together, we can conclude that in this pioneering 
study (considering microvibration testing in experimental 
hypertension) 10 minutes daily microvibration treat-
ment has no effect on blood pressure, but improves renal
blood supply (by diminishing renal vascular resistance), 
glomerular filtration and diuresis, with more important
role in hypertensive animals. Furthermore, it enhances 
glutathione-dependent antioxydative defence in SHR out of 
direct SOD stimulation. Relevance of these results appears 
as a material for further investigation, but it is reasonable 
to conclude that prolonged vibroacustic microvibrations 
have no obvious harmful effects and improve both renal
haemodynamic and glomerular filtration in hypertensive
rats. This could be beneficial in some pathological condi-
tions with affected renal function such as acute and chronic
kidney failure, but more pronounced preclinical studies are 
needed for definite conclusions.
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